Nasus Pharma Ltd (NSRX): Operating Income

Annual figures by period end, from SEC filings.

Figures out of scale. In this company's filings, reported revenue for the year ended 2025-12-31 is more than 100 times total assets. That usually means a value was tagged in the wrong unit. Figures are shown as filed; growth rates are not computed, and the company is left out of screens and comparisons.

-$4.90M
Year ended 2025-12-31. As filed; likely tagged in the wrong unit
2023-12-31: -$1.15M2024-12-31: -$1.08M2025-12-31: -$4.90M-$4.90M
2023-12-31 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31-$4.90Mn/a2026-03-25, From 2025-01-01
2024-12-31-$1.08Mn/a2026-03-25, From 2024-01-01
2023-12-31-$1.15Mn/a2026-03-25, From 2023-01-01